No Data
No Data
China Merchants Securities: Profit performance is better than revenue, and top OTC brands have stronger resilience.
In the first half of 2024, high-end scarce resources and traditional Chinese medicine OTC enterprises with brand and channel barriers performed well, while hospital-based traditional Chinese medicine enterprises were under short-term pressure due to industry policies and other factors.
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Could Easily Take On More Debt
Zhangzhou Pientzehuang Pharmaceutical's (SHSE:600436) Profits May Not Reveal Underlying Issues
Earnings Miss: Zhangzhou Pientzehuang Pharmaceutical., Ltd Missed EPS By 39% And Analysts Are Revising Their Forecasts
Zhangzhou Pientzehuang Pharmaceutical H1 Profit, Operating Income Up 12%
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.'s 2024 semi-annual report.
No Data
No Data